You are here: Industry Insights > Eli Lilly

News List

Pharma programmes for employees to volunteer in fight against COVID-19 europeanpharmaceuticalreview
April 07, 2020
Lilly, Merck and Pfizer have announced how they will enable their employees to volunteer in programmes to combat COVID-19 while on base pay.
Sitryx signs potential $880m drug development deal pharmaceutical-technology
April 02, 2020
UK-based biopharmaceutical firm Sitryx has entered into a licensing and research agreement with Eli Lilly to develop new disease-modifying drugs.
Lilly, Sitryx Enter Autoimmune Alliance contractpharma
April 01, 2020
To develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
FDA approves Lilly’s plaque psoriasis drug Taltz for children pharmaceutical-technology
April 01, 2020
The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) to treat moderate to severe plaque psoriasis in children aged six to below 18 years.
FDA hands Boehringer and Lilly complete response letter for insulin adjunct March 26, 2020
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
COVID-19 update: Eli Lilly assures security of insulin supply europeanpharmaceuticalreview
March 26, 2020
Having become aware of insulin shortages in pharmacies, the company has stated that its products are not backordered and should be available for delivery by wholesalers.
COVID-19: Gilead deals with ‘overwhelming’ remdesivir demands, Eli Lilly halts trial enrolment pharmatimes
March 25, 2020
As the UK comes to terms with significantly stricter lockdown rules this morning, following prime minister Boris Johnson’s speech last night ...
Boehringer, Lilly Get Complete Response Letter for Empagliflozin contractpharma
March 24, 2020
FDA is unable to approve sNDA for Empagliflozin in type 1 diabetes.
COVID-19 Update: Lilly Clinical Trial Activities contractpharma
March 24, 2020
Will delay most new study starts and pause enrollment in most ongoing studies due to the impact of the COVID-19 pandemic.
Eli Lilly receives breakthrough status for baricitinib in alopecia pharmaceutical-technology
March 18, 2020
Eli Lilly and its partner Incyte have received breakthrough therapy designation from the US Food and Drug Administration (FDA) for baricitinib to treat alopecia areata.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page